ELI LILLY & Co
Close on Nov 2, 2026Market cap $1.33TP/E 45.8Yield 0.44%
Eli Lilly Cardiometabolic Health — Outside U.S. revenue by Quarter
Cardiometabolic Health — Outside U.S. revenue ($M) ($M)
Eli Lilly Cardiometabolic Health — Outside U.S. revenue: $6,611M in Q2 2026, up 121.8% from a year earlier. That is the highest of the 13 quarters on record here.
Where the Q2 2026 figure comes from
Source: Form 10-Q (filed 2026-08-05) ↗
Reported in Form 10-Q / 10-K Note 2.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Cardiometabolic Health — Outside U.S. revenue ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 6,611 | +121.8% | Form 10-Q (filed 2026-08-05) ↗ |
| Q1 2026 | Mar 31, 2026 | 5,836 | +121.8% | Form 10-Q (filed 2026-04-30) ↗ |
| Q4 2025 | Dec 31, 2025 | 4,436 | +72.0% | Form 10-K (filed 2026-02-12) ↗ |
| Q3 2025 | Sep 30, 2025 | 4,311 | +128.1% | Form 10-Q (filed 2025-10-30) ↗ |
| Q2 2025 | Jun 30, 2025 | 2,980 | +65.7% | Form 10-Q (filed 2026-08-05) ↗ |
| Q1 2025 | Mar 31, 2025 | 2,631 | +87.5% | Form 10-Q (filed 2026-04-30) ↗ |
| Q4 2024 | Dec 31, 2024 | 2,579 | +101.2% | Form 10-K (filed 2026-02-12) ↗ |
| Q3 2024 | Sep 30, 2024 | 1,890 | +50.0% | Form 10-Q (filed 2025-10-30) ↗ |
| Q2 2024 | Jun 30, 2024 | 1,799 | +46.3% | Form 10-Q (filed 2025-08-07) ↗ |
| Q1 2024 | Mar 31, 2024 | 1,403 | – | Form 10-Q (filed 2025-05-01) ↗ |
| Q4 2023 | Dec 31, 2023 | 1,282 | – | Form 10-K (filed 2026-02-12) ↗ |
| Q3 2023 | Sep 30, 2023 | 1,260 | – | Form 10-Q (filed 2024-10-30) ↗ |
| Q2 2023 | Jun 30, 2023 | 1,230 | – | Form 10-Q (filed 2024-08-08) ↗ |
Cite this data
StockData. (2026). Eli Lilly Cardiometabolic Health — Outside U.S. revenue ($M), quarterly Q2 2023–Q2 2026 [Data set]. Compiled from Eli Lilly SEC filings and investor materials. https://stockdatahq.com/stocks/lly/kpis/ta-cardiometabolic-nonus
See every metric in the Eli Lilly KPI table. Data updated Oct 25, 2026.